Polycythemia pathophysiology

Polycythemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Polycythemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography or Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Polycythemia pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Polycythemia pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Polycythemia pathophysiology
CDC on Polycythemia pathophysiology
Polycythemia pathophysiology in the news
Blogs on Polycythemia pathophysiology
Directions to Hospitals Treating Polycythemia
Risk calculators and risk factors for Polycythemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]

Overview

The exact pathogenesis of [disease name] is not fully understood.

OR

It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].

OR

[Pathogen name] is usually transmitted via the [transmission route] route to the human host.

OR

Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.

OR

[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].

OR

The progression to [disease name] usually involves the [molecular pathway].

OR

The pathophysiology of [disease/malignancy] depends on the histological subtype.

Pathophysiology

Physiology

• Polycythemia is considered a diagnosis when hematocrit is >48% in women and >52% in men, and when hemoglobin is >16.5g/dL in women and >18.5g/dL in men.

• It is important that we know the similarities and differences between polycythemia and erythrocytosis.
• Similarities :

both are characterized by an increase in red blood cells in the blood. genetics may play a role in both disorders.

• Differences :

polycythemia is the increase in red blood cells and hemoglobin above normal. erythrocytosis is the increase in the mass of red blood cells. polycythemia may show an increase in white blood cells and platelets as well. increase in mass is limited to red blood cells only.

Pathogenesis

• The main mechanism by which polycythemia vera develops is a valine to phenylalanine substitution, precisely the JAK2V617F leading to constitutive activation of cytokine receptors. This mutation is present in over 90% of patients with PV, 50% to 60% in patients with primary myelofibrosis, and 50% with patients with essential thrombocythemia.
• Other factors contributing to the pathophysiology of polycythemia (amongst other myeloproliferative neoplasms) are blood cells, plasma factors, and the endothelial compartment.
• The role of platelets:

Several studies in people and in mouse models have shown the increase in platelet activation and coagulation by factors such as cell surface proteins namely; P-selectin (CD62P), or tissue factor(CD142), and circulating leuco-platelets aggregates. An increase in CD40 ligand, beta-thromboglobulin, platelet factor 4, thromboxane A2, and an increased expression of surface phosphatidylserine has been noted.

• The role of leukocytes:

Increased expression of CD11, CD14, and leukocyte alkaline phosphatase, which is further amplified in the event of a JAK2V617F mutation. The mutated macrophages also produce pro-inflammatory cytokines leading to further exaggeration of atherosclerosis which is responsible for myocardial infarction, cerebrovascular accidents, etc in these patients. The increase in adhesion of granulocytes in patients with the JAK2V617F mutation on integrin @4B1, ligand of VLA4 (either attached to a support or in a soluble form) has been shown in recent studies. In the mononuclear mutated cells, inhibition of activated Ras-proximate-1(small G- protein Rap 1) showed a reduction in cell adhesion, thereby proving that the JAK2V167F mutation is the cause of increased integrin expression (@4B1). NETs(Neutrophil Extracellular Traps): Decondensed DNA along with histones are responsible for activation of platelets, inhibition of anticoagulation molecules, and activation of the intrinsic coagulation pathway by factor XII activation.

• The role of red blood cells:

The Cytoreductive therapy in PV (CYTO-PV) clinical trial showed there is an increase in the risk of cardiovascular events in patients with >45% hematocrit; consequences depend on arterial or venous territory involvement. An amplified interaction between Lu/BCAM (erythroid Lutheran/ Basal cell adhesion molecule) and laminin accounts for qualitative abnormalities in red blood cells.

• The role of endothelial cells:

Activation of endothelial cells leading to increased levels of thrombomodulin, von Willebrand factor, both E and P selectins, and circulating endothelial cells. Some studies have shown that the enzyme heparanase leads to tissue factor inhibitor dissociation leading to pro coagulation. Both heparanase and tissue factor inhibitor have been found in increasing quantities in bone marrow samples of patients suffering from PV.

• The role of plasma:

D-dimers, thrombin-anti-thrombin complexes, F1 and F2 fibrinogen fragments are found to be in increased quantities. A reduction in serum protein C and S along with increased resistance to activated protein C is also noted. Extracellular vesicles of cytoplasmic membrane remnants called microparticles isolated from patients with JAK2617F mutation have shown to increase thrombin production.

Genetics

[Disease name] is transmitted in [mode of genetic transmission] pattern.

OR

Genes involved in the pathogenesis of [disease name] include:

• [Gene1]
• [Gene2]
• [Gene3]

OR

The development of [disease name] is the result of multiple genetic mutations such as:

• [Mutation 1]
• [Mutation 2]
• [Mutation 3]

Associated Conditions

Conditions associated with [disease name] include:

• [Condition 1]
• [Condition 2]
• [Condition 3]

Gross Pathology

On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Microscopic Pathology

On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].